Exhibit 99.1
Kura Oncology Announces Positive Phase 2 Trial of
Tipifarnib in PeripheralT-Cell Lymphoma
– Primary endpoint achieved with 45% and 42% ORR in AITL and CXCL12+
AITL/PTCL-NOS expansion cohorts –
– PTCL patients with tumors characterized by high CXCL12/CXCR4 expression ratio
experienced an ORR of 47% and a clinical benefit rate of 82% –
– 50% CR rate and 75% ORR observed in AITL patients with KIR mutations, a CXCL
pathway-associated marker –
– Company believes results support multiple registrational opportunities in
relapsed/refractory lymphoma and plans to seek regulatory feedback –
– Management to host conference call today at 8:00 a.m. ET –
SAN DIEGO, June 14, 2019 – Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced updated interim data from the ongoing Phase 2 clinical trial of its lead drug candidate, tipifarnib, in patients with relapsed or refractory peripheralT-cell lymphoma (PTCL).
The results, which will be presented during an oral session at 16:45 CET / 10:45 am ET tomorrow at the European Hematology Association (EHA) Annual Congress in Amsterdam, demonstrate ongoing anti-tumor activity and a manageable safety profile in advanced patients with angioimmunoblasticT-cell lymphoma (AITL) as well asnon-AITL PTCL. A copy of the presentation is available on the Company’s website atwww.kuraoncology.com.
“With additional follow up and new patients enrolled in the ongoing Phase 2 study, tipifarnib continues to demonstrate encouraging clinical activity in patients with relapsed or refractory PTCL who have experienced a median of three prior lines of therapy,” said Francine Foss, M.D., professor of medicine at the Yale Cancer Center, and a principal investigator in the trial. “Given the grim prognosis for late-stage PTCL patients, these data are exciting because they further validate tipifarnib as a targeted therapy and the potential for CXCL12 pathway biomarkers as effective enrichment strategies in late-stage PTCL patients with few therapeutic options.”